Ascletis Pharma Inc. Ascletis Pharma Inc.

Ascletis Pharma Inc.

1672

Rank in Stocks #11062
Ascletis Pharma Inc., a biotechnology company, engages in the research and... Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People’s Republic of China.
Share Price
$0.56085072
Last synced: 2026-11-19
Market Cap
$583.17M
Change (1 day)
0.70%
Change (1 year)
-69.58%
Country

Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this

Category

Healthcare
Operating Margin for Ascletis Pharma Inc. (1672)
Operating Margin as of November 2026 TTM: -70,395.30%
According to Ascletis Pharma Inc.'s latest financial reports, its current operating margin (TTM) is -70,395.30%. At the end of 2025 the company had an operating margin of -23,853.94%.
Operating Margin history for Ascletis Pharma Inc. from 2016 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) -70,395.30% 195.11%
2025 -23,853.94% 3.60%
2024 -23,025.64% 4,240.86%
2023 -530.44% -16.59%
2022 -635.94% 117.32%
2021 -292.63% -52.82%
2020 -620.30% 2,852.40%
2019 -21.01% -73.91%
2018 -80.52% -56.55%
2017 -185.33% 42.96%
2016 -129.64% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
-195.39% -100.00%
US
33.87% -100.00%
US
-116.04% -100.00%
US
25.57% -100.00%
AU
31.23% -100.00%
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.

Questions about Ascletis Pharma Inc.'s operating margin

What is Ascletis Pharma Inc.'s operating margin?

Ascletis Pharma Inc.'s operating margin is -70,395.30%, as of Nov 2026.

What was Ascletis Pharma Inc.'s operating margin in 2025?

In 2025, Ascletis Pharma Inc.'s operating margin was -23,853.94%, compared with -23,025.64% in 2024.

How has Ascletis Pharma Inc.'s operating margin changed since 2020?

From 2020 to 2025, Ascletis Pharma Inc.'s operating margin was highest in 2021 (-292.63%) and lowest in 2025 (-23,853.94%).

How does Ascletis Pharma Inc.'s operating margin compare with similar companies?

Ascletis Pharma Inc.'s operating margin (-70,395.30%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.